One hundred and eleven functionally significant mutations were discovered, and it was found that functionally significant mutations of SLC34A2 might be involved in the reduction of the life expectancy of breast (p.D68G, p.P504L) and thymus (p.A396T) cancer patients. Here, SLC34A2 is linked to cancer.